Meta-analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin.

ABSTRACT:

Background

Emerging data suggest that statins, aspirin and metformin may protect against hepatocellular carcinoma (HCC) development. However, prior meta-analyses were limited by heterogeneity and inclusion of studies without adequate adjustment for baseline risks.

Aim

To examine by an updated meta-analysis the association between these medications and HCC risk.

Methods

Medline and Embase databases were searched from inception to March 2022 for studies that balanced baseline risks between study groups via propensity score matching or inverse probability of treatment weighting, that reported the impact of statins, aspirin or metformin on HCC risk. Multivariable-adjusted hazard ratios (HRs) for HCC were pooled using a random effects model.

Results

Statin use was a

SUBMITTER: Zeng RW 

PROVIDER: S-EPMC10792521 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature